Evidence map›Paper›PMID 24316020›Full record

ArticleJournal of immunological methods2014

Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.

Heather E Lynch, Shelley M Stewart, Thomas B Kepler, Gregory D Sempowski, S Munir Alam

Abstract read
In one paragraph

Article in Journal of immunological methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Trial
  2. Article
  3. Altering the ligand specificity of DectiSomes.The Journal of biological chemistry · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heather E LynchDuke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
Shelley M StewartDuke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
Thomas B KeplerDepartment of Microbiology, Boston University School of Medicine, Boston, MA 02118, United States.
Gregory D SempowskiDuke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
S Munir AlamDuke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: alam0004@mc.duke.edu.

Funding

Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
NIAID NIH HHS UC6 AI058607NIAID NIH HHS UC6-AI58607PHS HHS HHSN266200500019C
6 · The paper itself

Abstract

Establishment of humoral immunity against pathogens is dependent on events that occur in the germinal center and the subsequent induction of high-affinity neutralizing antibodies. Quantitative assays that allow monitoring of affinity maturation and duration of antibody responses can provide useful information regarding the efficacy of vaccines and adjuvants. Using an anthrax protective antigen (rPA) and alum model antigen/adjuvant system, we describe a methodology for monitoring antigen-specific serum antibody concentration and avidity by surface plasmon resonance during primary and secondary immune responses. Our analyses showed that following a priming dose in mice, rPA-specific antibody concentration and avidity increases over time and reaches a maximal response in about six weeks, but gradually declines in the absence of antigenic boost. Germinal center reactions were observed early with maximal development achieved during the primary response, which coincided with peak antibody avidity responses to primary immunization. Boosting with antigen resulted in a rapid increase in rPA-specific antibody concentration and five-fold increase in avidity, which was not dependent on sustained GC development. The described methodology couples surface plasmon resonance-based plasma avidity measurements with germinal center analysis and provides a novel way to monitor humoral responses that can play a role in facilitating vaccine and adjuvant development.

Indexed as

Immunity, HumoralAdjuvants, ImmunologicAlum CompoundsAnimalsAnthraxAnthrax VaccinesAntibodies, BacterialAntibodies, NeutralizingAntibody AffinityAntibody SpecificityAntigens, BacterialBacillus anthracisBacterial ToxinsFemaleGerminal CenterImmunization, SecondaryAdjuvants, ImmunologicAlum Compoundsaluminum sulfateanthrax toxinAnthrax VaccinesAntibodies, BacterialAntibodies, NeutralizingAntigens, BacterialBacterial ToxinsAntibody avidityGerminal centersProtective antigen (PA)Surface plasmon resonance (SPR)

Identifiers

PMID24316020
PMCPMC4104170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.